CN1309971A - 一种治疗近视的滴眼剂 - Google Patents
一种治疗近视的滴眼剂 Download PDFInfo
- Publication number
- CN1309971A CN1309971A CN 01106489 CN01106489A CN1309971A CN 1309971 A CN1309971 A CN 1309971A CN 01106489 CN01106489 CN 01106489 CN 01106489 A CN01106489 A CN 01106489A CN 1309971 A CN1309971 A CN 1309971A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- eye drop
- myopia
- inosine
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 19
- 208000001491 myopia Diseases 0.000 title claims abstract description 18
- 230000004379 myopia Effects 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims abstract description 11
- 229930010555 Inosine Natural products 0.000 claims abstract description 11
- 229960003786 inosine Drugs 0.000 claims abstract description 11
- 239000003381 stabilizer Substances 0.000 claims abstract description 11
- YTLQFZVCLXFFRK-UHFFFAOYSA-N bendazol Chemical compound N=1C2=CC=CC=C2NC=1CC1=CC=CC=C1 YTLQFZVCLXFFRK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229950000900 bendazol Drugs 0.000 claims abstract description 8
- 239000008367 deionised water Substances 0.000 claims abstract description 8
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 8
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 claims abstract description 7
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 claims abstract description 7
- 229920005862 polyol Polymers 0.000 claims abstract description 3
- 150000003077 polyols Chemical class 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 10
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 10
- 230000002421 anti-septic effect Effects 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 9
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 9
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 229960004926 chlorobutanol Drugs 0.000 claims description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 6
- 229930003451 Vitamin B1 Natural products 0.000 abstract description 2
- 229930003779 Vitamin B12 Natural products 0.000 abstract description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 208000030533 eye disease Diseases 0.000 abstract description 2
- 229960003495 thiamine Drugs 0.000 abstract description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract description 2
- 235000010374 vitamin B1 Nutrition 0.000 abstract description 2
- 239000011691 vitamin B1 Substances 0.000 abstract description 2
- 235000019163 vitamin B12 Nutrition 0.000 abstract description 2
- 239000011715 vitamin B12 Substances 0.000 abstract description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 230000004402 high myopia Effects 0.000 abstract 1
- 239000002504 physiological saline solution Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 208000003464 asthenopia Diseases 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 210000001328 optic nerve Anatomy 0.000 description 5
- 210000002464 muscle smooth vascular Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 201000009487 Amblyopia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000004344 low myopia Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种治疗近视的滴眼剂,属眼科用配制品领域。主要由下列重量配比的药物的水溶液混配而成。地巴唑或山莨宕碱∶肌苷∶维生素B1∶三磷酸腺苷∶维生素B12=1－0.5∶1∶1－1.5∶1－1.5∶2.5。药物重量浓度为1.2－1.5%。所用水为去离子水、0.9%生理盐水或其混合物。其中可加入占药物溶液总重量2－18%的乙醇或多元醇稳定剂和0.25－1%的防腐剂,本发明对近视眼疾治疗效果好,尤其适用于400°以下视力的青少年患者。
Description
本发明属眼科用配制品技术领域，特别涉及一种治疗近视的滴眼剂。
目前，近视眼病已成为青少年中最常见疾病。据不完全统计，我国的近视眼病患者，青少年时期患病的发病率高达80％以上，现有的近视眼治疗药物及手术、仪器矫正等，有些疗程较长，有些收效甚微，有些愈合复发，有些花费甚巨，因此，亟待寻找一种长效、快速、方便的治疗方法及药物。
本发明目的在于提供一种能有效治疗近视的滴眼剂。
为达上述目的，本发明采用如下技术方案：一种治疗近视的滴眼剂，主要由下列重量配比的药物的水溶液混合而成：地巴唑或山莨宕碱∶肌苷∶维生素B1∶三磷酸腺苷∶维生素B12=1-0.5∶1∶1-1.5∶1-1.5∶2.5，药物重量浓度为1.2-1.5％。
药物重量配比为：地巴唑∶肌苷∶维生素B1∶三磷酸腺苷∶维生素B12=1∶1∶1∶1∶2.5。
药物重量配比为：山莨宕碱∶肌苷∶维生素B1∶三磷酸腺苷∶维生素B12=0.5∶1∶1∶1∶2.5。
药物水溶液中含占药液总量2-18％的乙醇或多元醇稳定剂和0.25％-1％的防腐剂。
药物水溶液用水为去离子水或/和0.9％生理盐水；稳定剂选用重量比75％的乙醇，用量18％；防腐剂选用苯氧乙醇，用量0.3-1％。
药物水溶液用水为去离子水或/和0.9％生理盐水；稳定剂选用甘油，用量为3％；防腐剂选用三氯叔丁醇，用量0.25-0.5％。
本发明为一种复方制剂，组方中地巴唑可解除血管平滑肌痉孪，恢复视神经疲劳，使受累的视神经功能恢复，治疗近视；山莨宕碱有扩瞳作用；肌苷可促进代谢，舒展血管平滑肌，抗调节性视疲劳；维生素B1可恢复视神经功能，抗视疲劳，治疗弱视；三磷酸腺苷有利于血管平滑肌舒张，可改进血液循环，缓冲睫状肌近视性痉孪，抵抗视疲劳；维生素B12则可恢复视神经功能，抗视疲劳及弱视。上述药物组成的本发明滴眼剂可降眼压、解除眼部疲劳，具有调节视神经功能，可使视力快速、平稳地恢复。对近视范围在400°以下患者治疗效果尤为显著，视力恢复甚至可达痊愈，且视力恢复情况稳定，不反复，无任何副作用。与其它眼用药物相比，治疗周期短，见效快，对低度近视及微近视，十天见效。治疗过程一般以45天为一个疗程。组方中无特殊贵重药物，治疗成本低。制成的眼药水可随身携带，随时点用，使用方便，使用本发明滴眼剂不会诱发角膜炎、砂眼等其它眼疾，尤其是停药后不会出现视力再度下降情况。
本发明滴眼剂制备方法为：取药物成份溶解于水，可为一般去离子水或0.9％生理盐水或其混合物，把其水溶液按药物配比混合均匀，若非即配即用，需加入甘油等稳定剂及防腐剂，混匀。
上述滴眼剂使用方法为：每天早中晚各点次每次2-3滴，最好同时带近视治疗眼镜(+300DS，球度0，色绿)，每日戴2次，每次30分钟。本滴眼剂稍有刺激性，本发明滴眼剂使用对象为近视眼疾患者，尤其是视力在400°以下的青少年患者。
下面通过实施例进一步说明本发明。
实施例1，一种治疗近视的滴眼剂，其中所含药物重量比例为：地巴唑∶肌苷∶维生素B1∶三磷酸腺苷∶维生素B12=1∶1∶1∶1∶2.5。药物重量浓度为1.5％。其制法为：取上述药物分别溶解于无菌去离子水形成药物水溶液，再按上述比例混合。向上述混合液中加入占混合液总重量3％的稳定剂甘油和0.25％的防腐剂三氯叔丁醇，混匀、分装即可。
实施例2，本实施例中，药物重量配比为地巴唑∶肌苷∶维生素B1∶三磷酸腺甘∶维生素B12=1∶1∶1∶1∶2.5。药物重量浓度为1.3％。稳定剂为乙醇，加量为18％，所用水为0.9％生理盐水。防腐剂为三氯叔丁醇，加量为0.5％。其他同实施例1。
实施例3，本实施例中，药物重量配比为山莨宕碱∶肌苷∶维生素B1∶三磷酸腺苷∶维生素B12=0.5∶1∶1∶1∶2.5。药物重量浓度为1.2％。所用水为去离子水和0.9％生理盐水混合物，二者比例1∶1，稳定剂为乙醇(75％)，加量为18％，防腐剂为苯氧乙醇，加量为1％，其他同实施例1。
Claims (6)
1、一种治疗近视的滴眼剂，本发明特征在于，主要由下列重量配比的药物的水溶液混合而成：地巴唑或山莨宕碱∶肌苷∶维生素B1∶三磷酸腺苷∶维生素B12=1-0.5∶1∶1-1.5∶1-1.5∶2.5，药物重量浓度为1.2-1.5％。
2、如权利要求1所述滴眼剂，其特征在于，药物重量配比为：地巴唑∶肌苷∶维生素B1∶三磷酸腺苷∶维生素B12=1∶1∶1∶1∶2.5。
3、如权利要求1所述的滴眼剂，其特征在于，药物重量配比为：山莨宕碱∶肌苷∶维生素B1∶三磷酸腺苷∶维生素B12=0.5∶1∶1∶1∶2.5。
4、如权利要求1、2、3所述的滴眼剂，其特征在于，药物水溶液中含占药液总量2-18％的乙醇或多元醇稳定剂和0.25％-1％的防腐剂。
5、如权利要求4所述的滴眼剂，其特征在于，药物水溶液用水为去离子水或/和0.9％生理盐水；稳定剂选用重量比75％的乙醇，用量18％；防腐剂选用苯氧乙醇，用量0.3-1％。
6、如权利要求4所述的滴眼剂，其特征在于，药物水溶液用水为去离子水或/和0.9％生理盐水；稳定剂选用甘油，用量为3％；防腐剂选用三氯叔丁醇，用量0.25-0.5％。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01106489 CN1132584C (zh) | 2001-02-19 | 2001-02-19 | 一种治疗近视的滴眼剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01106489 CN1132584C (zh) | 2001-02-19 | 2001-02-19 | 一种治疗近视的滴眼剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1309971A true CN1309971A (zh) | 2001-08-29 |
| CN1132584C CN1132584C (zh) | 2003-12-31 |
Family
ID=4655492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01106489 Expired - Fee Related CN1132584C (zh) | 2001-02-19 | 2001-02-19 | 一种治疗近视的滴眼剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1132584C (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094842A1 (en) * | 2004-03-30 | 2005-10-13 | Transition Therapeutics Inc. | Vitamin b12-containing compositions and methods of use |
| CN102525906A (zh) * | 2012-02-21 | 2012-07-04 | 轩红军 | 一种地巴唑滴眼液 |
| CN102836124A (zh) * | 2012-09-24 | 2012-12-26 | 南京京华生物工程有限公司 | 盐酸地巴唑滴眼液及其制备方法 |
| CN109908327A (zh) * | 2019-03-12 | 2019-06-21 | 广州陈锦济生物科技有限公司 | 一种用于治疗近视的眼药水及其制备方法 |
| EP3616723A4 (en) * | 2018-07-18 | 2020-03-25 | Wenzhou Medical University | METHOD FOR TREATING MYOPIA AND APPLICATION IN PRODUCING A MEDICINAL PRODUCT |
| CN112603926A (zh) * | 2020-12-30 | 2021-04-06 | 河南合智医药科技有限公司 | 一种治疗近视的阿托品肌苷滴眼剂及其制备方法 |
-
2001
- 2001-02-19 CN CN 01106489 patent/CN1132584C/zh not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094842A1 (en) * | 2004-03-30 | 2005-10-13 | Transition Therapeutics Inc. | Vitamin b12-containing compositions and methods of use |
| CN102525906A (zh) * | 2012-02-21 | 2012-07-04 | 轩红军 | 一种地巴唑滴眼液 |
| CN102836124A (zh) * | 2012-09-24 | 2012-12-26 | 南京京华生物工程有限公司 | 盐酸地巴唑滴眼液及其制备方法 |
| EP3616723A4 (en) * | 2018-07-18 | 2020-03-25 | Wenzhou Medical University | METHOD FOR TREATING MYOPIA AND APPLICATION IN PRODUCING A MEDICINAL PRODUCT |
| CN109908327A (zh) * | 2019-03-12 | 2019-06-21 | 广州陈锦济生物科技有限公司 | 一种用于治疗近视的眼药水及其制备方法 |
| CN112603926A (zh) * | 2020-12-30 | 2021-04-06 | 河南合智医药科技有限公司 | 一种治疗近视的阿托品肌苷滴眼剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1132584C (zh) | 2003-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0799615A1 (en) | Liposome eye drops | |
| JP7359204B2 (ja) | Ｎｉｔｍを予防及び治療するための医薬組成物及びその医薬用途 | |
| US5658896A (en) | Pharmaceutical composition regulating function of a living body | |
| KR20020021320A (ko) | 안과용 의약 조성물 | |
| CN103860625A (zh) | 越橘提取物眼用制剂及其制备方法和用途 | |
| US20020017305A1 (en) | Method of restoring endothelium of cornea | |
| CN108261390A (zh) | 一种布林佐胺溴莫尼定滴眼液及其制备方法 | |
| CN1132584C (zh) | 一种治疗近视的滴眼剂 | |
| CN116785290B (zh) | 苯环喹溴铵及其异构体在制备眼用制剂中的应用 | |
| AU2022243548A1 (en) | Water-soluble topical ophthalmic preparation containing lutein and production method thereof | |
| US20040192699A1 (en) | Optic nerve protecting agents containing alpha1 receptor blocker as active ingredient | |
| CN1141145C (zh) | 锝[99Tc]膦酸盐药物在制备治疗甲亢伴浸润性凸眼的药物中的应用 | |
| CN102512467A (zh) | 一种三七总皂苷的眼用制剂及其制备方法 | |
| EP3130335A1 (en) | Ophthalmic composition comprising inositol for improving visual accomodation | |
| RU2128975C1 (ru) | Глазные капли "баларпан" | |
| CN102240261A (zh) | 一种葡甘露聚糖注射液的制备方法及其医学用途 | |
| RU2469734C2 (ru) | Лечебное средство для лечения расстройств аккомодаций "stiak" | |
| CN105168237A (zh) | 一种复方凝胶保湿润眼液 | |
| CN105193776B (zh) | 一种复方视神经保护和抗青光眼药物组合物 | |
| CN120617408B (zh) | 用于眼部病症的中药组合物、中药贴剂、制备方法及应用 | |
| US20140079809A1 (en) | Compounds useful for the prevention or treatment of accommodative asthenopia | |
| JPH01290631A (ja) | 血管内皮細胞増殖抑制剤 | |
| CN109200016A (zh) | 一种苄达赖氨酸滴眼液及其制备方法与用途 | |
| RU2345740C1 (ru) | Способ лечения дистрофических заболеваний глаз грязелечебным средством "реликт-05" | |
| CN1306938C (zh) | 预防和治疗眼病的局部用药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1064427 Country of ref document: HK |